Romulus K. Brazzell - Mar 14, 2023 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)

Role
Head of Research and Development and Chief Medical Officer
Signature
/s/ Eric Trachtenberg, Attorney-in-Fact
Stock symbol
KALA
Transactions as of
Mar 14, 2023
Transactions value $
$0
Form type
4
Date filed
3/15/2023, 08:00 PM
Previous filing
Jan 6, 2023
Next filing
Jun 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALA Stock Option (Right to Buy) Award $0 +576 $0.00 576 Mar 14, 2023 Common Stock 576 $68.50 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 3, 2022, the Reporting Person was granted an option to purchase up to 2,160 shares of common stock of the Issuer. Specified portions of the options vest based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters.
F2 On March 14, 2023, the Compensation Committee of the Issuer's Board of Directors determined that certain of the performance conditions were achieved at specific levels of achievement, resulting in vesting of the option as to 576 shares of common stock. The Compensation Committee has made no determination with respect to certain performance metrics, which could result in the further vesting of up to 432 shares of common stock underlying the option.

Remarks:

Head of Research and Development and Chief Medical Officer